HealthMode

HealthMode, founded in 2017 by Dan Karlin and Bradford Cross, operated as a digital medicine and therapeutics company from its headquarters in San Francisco, California. The company specialized in using artificial intelligence-enabled digital measurement to enhance the precision and speed of clinical research and patient monitoring. Its core offering was a platform that facilitated low-friction, continuous data collection in real-world settings, providing detailed information for outcome analysis in clinical trials. This technology included wearable medical devices and smartphone applications, such as one designed to monitor coughs and respiratory symptoms, which could remotely track various physical and biological parameters of a patient for research purposes.

The business model was centered on providing these advanced measurement solutions to clinical researchers and drug developers. By integrating clinical trial data with real-world evidence, HealthMode aimed to help its clients make more informed decisions, reduce uncertainty, and accelerate the development of new treatments. The founders brought pertinent expertise to the venture; Dr. Daniel Karlin, who served as CEO, is a medical doctor and had a background as a pharmaceutical veteran, including a leadership role at Pfizer's Neuroscience Research Unit. Co-founder Bradford Cross, who later became CTO, was a former Google AI/ML industry veteran and a founding partner at the deep tech venture capital fund, Data Collective (DCVC).

A significant milestone in the company's history was its acquisition by MindMed, a psychedelic medicine biotech company, which was finalized in February 2021. The deal was valued at approximately $32 million, consisting of MindMed shares and a small cash payment. Through this acquisition, MindMed gained HealthMode's intellectual property, its clinical trial platforms, and its 24-person team. Karlin and Cross joined MindMed's executive team as Chief Medical Officer and Chief Technology Officer, respectively, following the acquisition. The acquisition was a strategic move for MindMed to build a comprehensive digital mental health platform, integrating HealthMode's technology to support the development and eventual commercialization of psychedelic-assisted therapies.

Keywords: digital medicine, clinical research, patient monitoring, artificial intelligence, healthcare technology, clinical trials, digital therapeutics, AI-enabled measurement, real-world evidence, remote patient monitoring, drug development, data collection, digital health, HealthTech, wearable devices, biometrics, machine learning in healthcare, clinical data management, pharmaceutical technology, MindMed acquisition